Glycosylated Peptide Market by Segmentation: Based on Product, Application and Region, Forecast 2026 | Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, GlyTech, Inc., Sussex Research Laboratories Inc., Samsung Bioepis, and Celltrion Inc.
Glycosylated Peptide |
Glycosylated peptide are employed as important biological function mediators with distinct intrinsic features that have the ability to cure a wide range of disorders. Glycosylation of peptide medicines has several advantages, including enhanced half-life, longer dose duration, higher solubility, and greater therapeutic response. The advantages of these peptides that demonstrate significant biological activity, the availability of new peptides in the market, and the rise in the incidence of chronic illnesses globally are the primary drivers driving market expansion.
However, market development is constrained by the inherent complexity of production and the high cost of the active pharmaceutical ingredient (API). Nonetheless, continued research and development initiatives, as well as increased investment by pharmaceutical corporations, provide sufficient prospects for Glycosylated peptide market expansion.
Glycosylated Peptide Market Key Segments:
By Product Type
- Monoclonal Antibodies (MABs)
- Erythropoietin (EPO)
- Others
By Application
- Oncology
- Blood Disorder
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Some Advantages of glycosylated peptides include:
- Increased bioavailability
- Increased metabolic stability
- Targeting specific tissues and organs
- Reduction in clearance rates
- Enhanced receptor binding
- Facilitation of active transport across cell membranes
- Maintaining the overall physical properties of peptides
Due to developing market players and their market expansion plans, Asia Pacific is predicted to rise significantly. In 2017, for example, Amgen partnered with Simcere Pharmaceutical Group in China to co-develop and commercialise its biosimilar medicines as well as four unannounced pipeline biosimilar candidates for the treatment of inflammation and cancer.
The major key players operating in glycosylated peptide market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, GlyTech, Inc., Sussex Research Laboratories Inc., Samsung Bioepis, and Celltrion Inc.
Comments
Post a Comment